AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/894fed4415b7d60d1c0c1ad6f05fb5c5a24a5947" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AstraZeneca Investors See Little Logic in Bristol Tie-Up"></iframe>
